Publikationen in Zusammenarbeit mit Forschern von Fundación Hospital Alcorcón (49)

2024

  1. Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2

  2. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports

  3. Repercussion of psoriasis on the emotional health, well-being and quality of life of patients: A descriptive cross-sectional study

    Piel, Vol. 39, Núm. 4, pp. 185-192

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

  5. The error of estimated GFR in predialysis care

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Expert recommendations for the use of apremilast in psoriatic arthritis

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 34-44

  2. Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: The advantage study

    United European Gastroenterology Journal, Vol. 11, Núm. 7, pp. 692-699

  3. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

  4. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes

    Gut, Vol. 71, Núm. 10, pp. 2138-2140

  2. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  3. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

2021

  1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  2. Predictors of clinically significant quality of life impairment in Parkinson’s disease

    npj Parkinson's Disease, Vol. 7, Núm. 1

  3. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

    Kidney International Reports, Vol. 6, Núm. 9, pp. 2392-2403

2020

  1. The impact of freezing of gait on functional dependency in Parkinson’s disease with regard to motor phenotype

    Neurological Sciences, Vol. 41, Núm. 10, pp. 2883-2892

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

    European Journal of Surgical Oncology, Vol. 45, Núm. 10, pp. 1876-1881

  3. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation

    European Journal of Neurology, Vol. 26, Núm. 11, pp. 1399-1407

  4. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

    Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672